In our study, the high expression of CD25 on peripheral blood immune cells was detected in EGFR-TKI resistant NSCLC patients, suggesting that PD-1/PD-L1 monoclonal antibody combined with CD25 inhibitors may further improve the immunotherapy efficacy of this population. Here, PDCD1 is linked to non-small cell lung carcinoma.